Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control.
暂无分享,去创建一个
[1] D. Maher,et al. Guidelines for the Management of Drug-resistant Tuberculosis , 1997 .
[2] L. Karasulu,et al. The treatment of multidrug-resistant tuberculosis in Turkey. , 2001, The New England journal of medicine.
[3] S. Rüsch-Gerdes,et al. A case-control study for multidrug-resistant tuberculosis: risk factors in four European countries. , 2005, Microbial drug resistance.
[4] S. Niemann,et al. The Beijing genotype is a major cause of drug-resistant tuberculosis in Kazakhstan. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[5] F. Drobniewski,et al. Molecular Techniques in the Diagnosis of Mycobacterium tuberculosis and the Detection of Drug Resistance , 2001, Annals of the New York Academy of Sciences.
[6] R. O'brien,et al. The use of restriction fragment length polymorphism (RFLP) analysis for epidemiological studies of tuberculosis in developing countries. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[7] H S F Fraser,et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[8] R. Baltussen,et al. Cost effectiveness analysis of strategies for tuberculosis control in developing countries , 2005, BMJ : British Medical Journal.
[9] Robert C. Reynolds,et al. Preclinical Testing of the Nitroimidazopyran PA-824 for Activity against Mycobacterium tuberculosis in a Series of In Vitro and In Vivo Models , 2005, Antimicrobial Agents and Chemotherapy.
[10] I. Bastian,et al. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[11] L. Blumberg,et al. Rapid indication of multidrug-resistant tuberculosis from liquid cultures using FASTPlaqueTB-RIF, a manual phage-based test. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[12] S. Sharma,et al. Progress of DOTS in global tuberculosis control , 2006, The Lancet.
[13] Naresh J. Patel,et al. Effect of an immunomodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis. , 2002, Journal of the Indian Medical Association.
[14] V. Jarlier,et al. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. , 1999, American journal of respiratory and critical care medicine.
[15] L. P. Ormerod. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. , 2005, British medical bulletin.
[16] N. Ahmed,et al. Mycobacterium tuberculosis Isolate with a Distinct Genomic Identity Overexpresses a Tap-Like Efflux Pump , 2004, Infection.
[17] Nalin Rastogi,et al. Predominant Tuberculosis Spoligotypes, Delhi, India , 2004, Emerging infectious diseases.
[18] M. Putman,et al. Molecular Properties of Bacterial Multidrug Transporters , 2000, Microbiology and Molecular Biology Reviews.
[19] J. Musser,et al. Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities , 1997, Antimicrobial agents and chemotherapy.
[20] Naresh J. Patel,et al. Improved cure rates in pulmonary tuberculosis category II (retreatment) with mycobacterium w. , 2003, Journal of the Indian Medical Association.
[21] P. Small,et al. Does DOTS work in populations with drug-resistant tuberculosis? , 2005, The Lancet.
[22] S. Niemann,et al. The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia , 2005, Respiratory research.
[23] T. Frieden,et al. The DOTS strategy for controlling the global tuberculosis epidemic. , 2005, Clinics in chest medicine.
[24] T. Tupasi,et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[25] N. Binkin,et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[26] R. O'brien,et al. New drugs for tuberculosis: current status and future prospects. , 2005, Clinics in chest medicine.
[27] N. Ahmed,et al. Genomics of Mycobacterium tuberculosis: old threats & new trends. , 2004, The Indian journal of medical research.
[28] J. Musser,et al. Molecular diagnosis of mycobacteria. , 2001, Clinical chemistry.
[29] D. Snider,et al. Multidrug-resistant Tuberculosis , 1992, Annals of Internal Medicine.
[30] J. Grange,et al. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. , 2004, Frontiers in bioscience : a journal and virtual library.
[31] Philip Supply,et al. Automated High-Throughput Genotyping for Study of Global Epidemiology of Mycobacterium tuberculosis Based on Mycobacterial Interspersed Repetitive Units , 2001, Journal of Clinical Microbiology.
[32] F. Drobniewski,et al. A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK , 2002, Thorax.
[33] Donna Neuberg,et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. , 2003, The New England journal of medicine.
[34] T. Holtz,et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study , 2005, The Lancet.
[35] K. Mate,et al. From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift. , 2003, Tuberculosis.
[36] J. Stanford,et al. Immunotherapy for drug-resistant tuberculosis , 1992, The Lancet.
[37] R. Coninx,et al. First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons , 1999, The Lancet.
[38] W. Rom,et al. Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. , 1996, American journal of respiratory and critical care medicine.
[39] Molecular Genotyping of a Large, Multicentric Collection of Tubercle Bacilli Indicates Geographical Partitioning of Strain Variation and Has Implications for Global Epidemiology of Mycobacterium tuberculosis , 2004, Journal of Clinical Microbiology.
[40] J. T. Crawford,et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. , 1992, The New England journal of medicine.
[41] Preeti Gupta,et al. Ring-substituted imidazoles as a new class of anti-tuberculosis agents. , 2004, European journal of medicinal chemistry.
[42] L. Lambert,et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[43] S. Asch,et al. Relationship of isoniazid resistance to human immunodeficiency virus infection in patients with tuberculosis. , 1996, American journal of respiratory and critical care medicine.
[44] A. Mohan,et al. Scientific basis of directly observed treatment, short-course (DOTS). , 2003, Journal of the Indian Medical Association.
[45] N. K. Jain,et al. Clinical and genetic risk factors for the development of multi-drug resistant tuberculosis in non-HIV infected patients at a tertiary care center in India: a case-control study. , 2003, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[46] J. T. Crawford,et al. Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. , 1993, The Journal of infectious diseases.
[47] A. Alrajhi,et al. Risk factors for drug-resistant Mycobacterium tuberculosis in Saudi Arabia. , 2002, Saudi medical journal.
[48] M. Espinal,et al. Increasing transparency in partnerships for health – introducing the Green Light Committee , 2002, Tropical medicine & international health : TM & IH.
[49] G. Peersman,et al. A survey of drug-resistant Mycobacterium tuberculosis and its relationship to HIV infection. , 1998 .
[50] F. Drobniewski,et al. The use of macroarrays for the identification of MDR Mycobacterium tuberculosis. , 2006, Journal of microbiological methods.
[51] Charles L Daley,et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. , 2003, American journal of respiratory and critical care medicine.
[52] A. Mirzabekov,et al. Evaluation of hybridisation on oligonucleotide microarrays for analysis of drug-resistant Mycobacterium tuberculosis. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[53] A. Fraser,et al. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[54] A. Khomenko,et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. , 2000, JAMA.
[55] R. Urbanczik,et al. Laboratory diagnostic aspects of drug resistant tuberculosis. , 2004, Frontiers in bioscience : a journal and virtual library.
[56] S. Han,et al. Association of HLA-DR and HLA-DQ genes with susceptibility to pulmonary tuberculosis in Koreans: preliminary evidence of associations with drug resistance, disease severity, and disease recurrence. , 2005, Human immunology.
[57] Hinrich W. H. Göhlmann,et al. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.
[58] Clifton E. Barry,et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.
[59] J. Musser,et al. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. , 1998, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.